Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Stifel CNS Days (Virtual) Transcript

Mar 29, 2023 / 03:00PM GMT
Release Date Price: €39.68 (+0.63%)
Paul Matteis
Stifel Financial Corp. - Analyst

Great. Thanks very much, everybody. It's my pleasure to be moderating a panel with the Sage Therapeutics team. With me is Kimi Iguchi, CFO; Chris Benecchi, Chief Commercial Officer; and Jim Doherty, Chief Development Officer.

Questions & Answers

Paul Matteis
Stifel Financial Corp. - Analyst

I don't think we need any background. I think folks know what you guys are about. So maybe we can kind of get started. And obviously, probably somewhat limited on what you can say, but maybe, Jim, could you just sort of speak to how the regulatory process is going for zuranolone?

We're really surprised that there's not an AdCom. I mean, that's certainly a good thing. No AdCom, no priority review is usually great, but were you surprised?

Jim Doherty
Sage Therapeutics, Inc. - Chief Development Officer

Happy to, Paul. Well, good to see you again. And thanks, everyone, for joining. Busy time at Sage, speaking specifically to the zuranolone program regulatory status.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot